Loading
A phase 2 trial of Sacituzumab govitecan, Pembrolizumab, Cisplatin, Avelumab, Zimberelimab and Carboplatin in bladder & urothelial cancer, run by Gilead Sciences, active and no longer recruiting.
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread is a phase 2 interventional study registered as NCT03547973 by Gilead Sciences, with 502 participants enrolled, started 2018-08-13 and due to reach its primary completion in 2030-04. Interventions recorded: Sacituzumab Govitecan-hziy, Pembrolizumab, Cisplatin, Avelumab, Zimberelimab and Carboplatin.
Shares Avelumab, Muscle-invasive and advanced bladder cancer, Sacituzumab govitecan, Bladder & urothelial cancer and the tag pipeline.
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer, Cisplatin, Carboplatin and the tag pipeline.
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Bladder & urothelial cancer and the tag pipeline.
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Topoisomerase-I inhibitors (and ADC payloads), Bladder & urothelial cancer, Antibody-drug conjugate (ADC) and the tag pipeline.